Vascarta

transdermal delivery, curcumin, linker chemistry

modulatingsmall molecule

vascarta.com·New York City, New York, United States·

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-CBKU

Summary · Eternal Search editorial

Vascarta transdermal delivery, curcumin, linker chemistry

Vascarta is a clinical-stage pharmaceutical company focused on improving established therapies through transdermal delivery and linker technology. Its lead product candidate, VAS-101/Vasceptor, uses topical transdermal curcumin delivery to address bioavailability limitations of oral curcumin. The company lists clinical programs in sickle cell disease and osteoarthritis, and preclinical work in red blood cell preservation, hypertension, anti-aging/dementia, brain cancer, and pancreatic cancer.

The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →

Plate C·01 · Scientific profile

All 16 dimensions
on the record.

Composite34

Chain scale100 pts

Dimensions16

Plate C·02 · Where it sits among peers

Score vs. proximity
to longevity goals.

Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.

Reading

Vascarta — Early mechanism · Lower middle. Derived deterministically from 10 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (8 programs at preclinical).…

Source: Deterministic

At a glance

Webvascarta.com

HQNew York City, New York, United States

Publications

13 on file

012026The effect of a topical curcumin formulation (VAS-101) on knee pain in adults with knee osteoarthritis: A randomised, double-blind, placebo-controlled study—→022026Novel transdermal curcumin attenuates cisplatin induced neuropathy in a mouse model of breast cancer—→032026A novel transdermal curcumin gel shows potential in improving cardiac bioenergetic functions in Berkeley sickle cell mice—→042026A novel transdermal curcumin gel shows potential in improving cardiac bioenergetic functions in Berkeley sickle cell mice.Blood vessels, thrombosis & hemostasis→052025Salutary effects of transdermal curcumin on multiple indices of health span in rodent models of normal aging and hypertension—→062025Targeting sickle cell pathobiology and pain with novel transdermal curcumin.PNAS nexus→072025Targeting sickle cell pathobiology and pain with novel transdermal curcumin—→082025Mechanisms of acute pain involve spinal IL17-TNF-α/IL-6–p38 MAPK activation in sickle cell disease—→092024Biopreservation and reversal of oxidative injury during blood storage by a novel curcumin-based gel formulation.Scientific reports→102024Biopreservation and reversal of oxidative injury during blood storage by a novel curcumin-based gel formulation—→112024Biopreservation and Reversal of Oxidative Injury During Blood Storage by a Novel Curcumin-based Gel Formulation.Research square→122023Novel transdermal curcumin therapeutic preserves endothelial barrier function in a high-dose LPS rat model.Artificial cells, nanomedicine, and biotechnology→132023Novel transdermal curcumin therapeutic preserves endothelial barrier function in a high-dose LPS rat model—→

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Vascarta

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

Loading

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.